268 related articles for article (PubMed ID: 24715588)
1. Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models.
Gravina GL; Marampon F; Sherris D; Vittorini F; Di Cesare E; Tombolini V; Lenzi A; Jannini EA; Festuccia C
Prostate; 2014 Jun; 74(8):852-68. PubMed ID: 24715588
[TBL] [Abstract][Full Text] [Related]
2. The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.
Gravina GL; Marampon F; Petini F; Biordi L; Sherris D; Jannini EA; Tombolini V; Festuccia C
Endocr Relat Cancer; 2011 Aug; 18(4):385-400. PubMed ID: 21551258
[TBL] [Abstract][Full Text] [Related]
3. Keloid disease can be inhibited by antagonizing excessive mTOR signaling with a novel dual TORC1/2 inhibitor.
Syed F; Sherris D; Paus R; Varmeh S; Singh S; Pandolfi PP; Bayat A
Am J Pathol; 2012 Nov; 181(5):1642-58. PubMed ID: 22982188
[TBL] [Abstract][Full Text] [Related]
4. The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer.
Diaz R; Nguewa PA; Diaz-Gonzalez JA; Hamel E; Gonzalez-Moreno O; Catena R; Serrano D; Redrado M; Sherris D; Calvo A
Br J Cancer; 2009 Mar; 100(6):932-40. PubMed ID: 19240717
[TBL] [Abstract][Full Text] [Related]
5. The enhancement of tumor radioresponse by combined treatment with cepharanthine is accompanied by the inhibition of DNA damage repair and the induction of apoptosis in oral squamous cell carcinoma.
Harada T; Harada K; Ueyama Y
Int J Oncol; 2012 Aug; 41(2):565-72. PubMed ID: 22664937
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo radiosensitization of colorectal cancer HT-29 cells by the smac mimetic JP-1201.
Huerta S; Gao X; Livingston EH; Kapur P; Sun H; Anthony T
Surgery; 2010 Aug; 148(2):346-53. PubMed ID: 20633731
[TBL] [Abstract][Full Text] [Related]
7. Epothilone B confers radiation dose enhancement in DAB2IP gene knock-down radioresistant prostate cancer cells.
Kong Z; Raghavan P; Xie D; Boike T; Burma S; Chen D; Chakraborty A; Hsieh JT; Saha D
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1210-8. PubMed ID: 20970033
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib.
Raju U; Ariga H; Dittmann K; Nakata E; Ang KK; Milas L
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):520-8. PubMed ID: 16168844
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
Chinnaiyan P; Huang S; Vallabhaneni G; Armstrong E; Varambally S; Tomlins SA; Chinnaiyan AM; Harari PM
Cancer Res; 2005 Apr; 65(8):3328-35. PubMed ID: 15833866
[TBL] [Abstract][Full Text] [Related]
10. The mechanism of radiosensitization by YM155, a novel small molecule inhibitor of survivin expression, is associated with DNA damage repair.
Hu S; Fu S; Xu X; Chen L; Xu J; Li B; Qu Y; Yu H; Lu S; Li W
Cell Physiol Biochem; 2015; 37(3):1219-30. PubMed ID: 26418254
[TBL] [Abstract][Full Text] [Related]
11. A radiosensitizing effect of artesunate in glioblastoma cells is associated with a diminished expression of the inhibitor of apoptosis protein survivin.
Reichert S; Reinboldt V; Hehlgans S; Efferth T; Rödel C; Rödel F
Radiother Oncol; 2012 Jun; 103(3):394-401. PubMed ID: 22560712
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo.
Maggiorella L; Deutsch E; Frascogna V; Chavaudra N; Jeanson L; Milliat F; Eschwege F; Bourhis J
Cancer Res; 2003 May; 63(10):2513-7. PubMed ID: 12750274
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells.
Gao H; Xue J; Zhou L; Lan J; He J; Na F; Yang L; Deng L; Lu Y
Cancer Lett; 2015 Aug; 365(1):79-88. PubMed ID: 25982206
[TBL] [Abstract][Full Text] [Related]
14. Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions.
Potiron VA; Abderrahmani R; Giang E; Chiavassa S; Di Tomaso E; Maira SM; Paris F; Supiot S
Radiother Oncol; 2013 Jan; 106(1):138-46. PubMed ID: 23321494
[TBL] [Abstract][Full Text] [Related]
15. Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma.
Reichert S; Rödel C; Mirsch J; Harter PN; Tomicic MT; Mittelbronn M; Kaina B; Rödel F
Radiother Oncol; 2011 Oct; 101(1):51-8. PubMed ID: 21852011
[TBL] [Abstract][Full Text] [Related]
16. Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity.
Konsoula Z; Cao H; Velena A; Jung M
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1541-8. PubMed ID: 21277099
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage.
Marampon F; Gravina G; Ju X; Vetuschi A; Sferra R; Casimiro M; Pompili S; Festuccia C; Colapietro A; Gaudio E; Di Cesare E; Tombolini V; Pestell RG
Oncotarget; 2016 Feb; 7(5):5383-400. PubMed ID: 26689991
[TBL] [Abstract][Full Text] [Related]
18. DMAPT inhibits NF-κB activity and increases sensitivity of prostate cancer cells to X-rays in vitro and in tumor xenografts in vivo.
Mendonca MS; Turchan WT; Alpuche ME; Watson CN; Estabrook NC; Chin-Sinex H; Shapiro JB; Imasuen-Williams IE; Rangel G; Gilley DP; Huda N; Crooks PA; Shapiro RH
Free Radic Biol Med; 2017 Nov; 112():318-326. PubMed ID: 28782644
[TBL] [Abstract][Full Text] [Related]
19. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of glycogen synthase kinase-3beta promotes nuclear export of the androgen receptor through a CRM1-dependent mechanism in prostate cancer cell lines.
Schütz SV; Cronauer MV; Rinnab L
J Cell Biochem; 2010 Apr; 109(6):1192-200. PubMed ID: 20127713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
